| Title: |
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm |
| Authors: |
Charlie Yang; Christine Brezden-Masley; Anil Abraham Joy; Sandeep Sehdev; Shanu Modi; Christine Simmons; Jan-Willem Henning |
| Source: |
Therapeutic Advances in Medical Oncology, Vol 15 (2023) |
| Publisher Information: |
SAGE Publishing, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282 |
| Description: |
The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival benefit among patients with hormone receptor-positive and hormone receptor-negative disease and low expression of HER2, a biomarker previously considered unactionable in this treatment setting. Herein, we discuss the evolving therapeutic pathway for HER2-low disease, ongoing clinical trials, and the potential challenges and evidence gaps arising with treatment of this patient population. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1758-8359 |
| Relation: |
https://doaj.org/toc/1758-8359 |
| DOI: |
10.1177/17588359231175440 |
| Access URL: |
https://doaj.org/article/a17a60d6565c4e98af4e3ce41005cbcc |
| Accession Number: |
edsdoj.17a60d6565c4e98af4e3ce41005cbcc |
| Database: |
Directory of Open Access Journals |